Fig. 1 · Structure

Documents & Downloads

PF-3758309

Cat. No. A11930 CAS 898044-15-0

PAK4 inhibitor

PF-3758309 is a small-molecule p21-activated kinase inhibitor inhibiting oncogenic signaling and tumor growth.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PAK4 IC50 1.3nM
PAK1 ki 13.7nM
PAK6 ki 17.1nM
PAK5 ki 18.1nM
PAK4 ki 18.7nM
PAK3 IC50 99nM
PAK2 IC50 190nM

7 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 0.463 μM Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay [PMID: 29886323]
HCT-116 IC50 0.039 μM Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay [PMID: 29886323]
MDA-MB-436 IC50 0.79 nM Cytotoxicity against human MDA-MB-436 cells assessed as reduction in cell viability after 24 to 48 hrs by Celltiter-glo luminescence assay [PMID: 24432870]

PF-3758309 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of PF-3758309 from 3 published references. In vitro models include MDCKII-LE cells; HCT116 cells.

PF-3758309 In Vitro Studies

PF-3758309 showed permeability of 0.9 × 10−6 cm/s in MDCKII-LE transwell assays. In HCT116 cells treated for 24 h, 4935 genes were upregulated and 6544 genes were downregulated at the mRNA level. Treatment at 1 μmol/L for 8 h decreased P-S675 in the PF-3758309-sensitive HCT116 cell line. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Transwell Permeability in MDCKII-LE Cells

Cell-based study · MDCKII-LE cells [1]

The study compound was evaluated in MDCKII-LE cells using transwell assays with DMSO as the vehicle. A permeability value was reported.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
permeabilitypermeability 0.9 × 10−6 cm/s[1]

Literature-Reported Treatment Conditions

Method
transwell assays
Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose, schedule, control.
Methods and source locations

Compound reported in the paper: PF-3758309; Compound label in the paper: PF-309

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Chemicals and reagents (S2); Results > PF-3758309 is a substrate for P-glycoprotein and breast cancer resistance protein (S94, S95)

permeability: permeability — Results > PF-3758309 is a substrate for P-glycoprotein and breast cancer resistance protein (S95)

Treatment Alters mRNA Levels in HCT116 Cells

Cell-based study · HCT116 cells [2]

In HCT116 cells treated with the study compound for 24 h, 4935 genes were upregulated and 6544 genes were downregulated at the mRNA level relative to the DMSO control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Global changes in mRNA levelsmRNA levels 4935 genes were upregulated and 6544 genes were downregulated[2]

Literature-Reported Treatment Conditions

Exposure duration
24 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose, route.
Methods and source locations

Compound reported in the paper: PF-3758309

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Multi-Omics analysis identified new potential targets of PF-3758309 (S15, S32); Materials and methods > RNA-seq (S197)

Global changes in mRNA levels: Global changes in mRNA levels; comparator: DMSO — Results > Multi-Omics analysis identified new potential targets of PF-3758309 (S15, S32)

Reduced phosphorylation readout in a sensitive cell line

Cell-based study · HCT116 [3]

PF-3758309 treatment at 1 μmol/L for 8 h decreased P-S675 in the PF-3758309-sensitive HCT116 cell line.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
P-S675Reported result a decrease in P-S675 in the PF-3758309 sensitive cell line, HCT116[3]

Literature-Reported Treatment Conditions

Treatment concentration
1 μmol/L
Exposure duration
8 h
Method
treated
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: control.
Methods and source locations

Compound reported in the paper: PF-3758309

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > CELL CULTURE AND PROLIFERATION (S8); RESULTS > EVALUATION OF DOWNSTREAM EFFECTORS BY A PHOSPHO-KINASE ARRAY AND IMMUNOBLOTTING (S107); FIGURE 3 legend (S143)

P-S675: P-S675 — RESULTS > EVALUATION OF DOWNSTREAM EFFECTORS BY A PHOSPHO-KINASE ARRAY AND IMMUNOBLOTTING (S107)

PF-3758309 In Vivo Studies

In female athymic nude mice bearing HCT116 tumors, the study compound was administered by oral gavage at 25 mg/kg twice daily for 14 days. Tumor volumes showed statistically significant tumor growth inhibition compared with vehicle control (p = 0.009). [3]

Tumor growth inhibition in mice receiving oral treatment

Animal study · Five- to six-week-old female athymic nude mice (Harlan Sprague Dawley); HCT116; at least 10 tumors per group [3]

In female athymic nude mice bearing HCT116 tumors, the study compound was administered by oral gavage at 25 mg/kg twice daily for 14 days. Tumor volumes showed statistically significant tumor growth inhibition compared with vehicle control (p = 0.009).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volumesReported result statistically significant tumor growth inhibition (p = 0.009[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
14 days; twice daily
Vehicle
0.5% methylcellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PF-3758309 25 mg/kgvehicle control (0.5% methylcellulose)statistically significant tumor growth inhibition (p = 0.009[3]
PF-3758309 25 mg/kg
Model: Five- to six-week-old female athymic nude mice (Harlan Sprague Dawley); HCT116; at least 10 tumors per group
Methods and source locations

Compound reported in the paper: PF-3758309

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > IN VIVO XENOGRAFT TREATMENT (S71, S75, S78, S79); RESULTS > IN VIVO VALIDATION OF PF-3758309 SENSITIVITY AND ASSESSMENT OF EMT MARKERS (S119, S120)

Tumor volumes: Tumor volumes; comparator: vehicle control (0.5% methylcellulose) — RESULTS > IN VIVO VALIDATION OF PF-3758309 SENSITIVITY AND ASSESSMENT OF EMT MARKERS (S120)

PF-3758309 25 mg/kg · MATERIALS AND METHODS > IN VIVO XENOGRAFT TREATMENT (S79); RESULTS > IN VIVO VALIDATION OF PF-3758309 SENSITIVITY AND ASSESSMENT OF EMT MARKERS (S120)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 898044-15-0
Applications PAK4 inhibitor
Formula C25H30N8OS
Molecular Weight 490.2
Synonyms PF-03758309
SMILES
CC1=NC2=C(C(=N1)NC3=NNC4=C3CN(C4(C)C)C(=O)N[C@H](CN(C)C)C5=CC=CC=C5)SC=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 87 mg/mL (177.32 mM)
Water Insoluble
Ethanol 87 mg/mL (177.32 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PF-3758309 Research References

  1. [1] Bradshaw-Pierce EL, Pitts TM, Tan AC, et al. Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Front Pharmacol (2013). PMID: 23524533 DOI: 10.3389/fphar.2013.00022 Source material
  2. [2] Jia X, Zhang J, Pan L, et al. Multi-omics analysis reveals RNA polymerase II degradation as a novel mechanism of PF-3758309's anti-tumor activity. Cell Death Discov (2025). PMID: 40854914 DOI: 10.1038/s41420-025-02677-5 Source material
  3. [3] Pitts TM, Kulikowski GN, Tan AC, et al. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol (2013). PMID: 23543898 DOI: 10.3389/fphar.2013.00035 Source material

Added to your cart

View Cart Checkout
Loading...